Mu-opioid receptor coupling to gα o plays an important role in opioid antinociception

Neuropsychopharmacology

Volumn 36, Issue 10, 2011, Pages 2041-2053

  Lamberts, Jennifer T ^a   Jutkiewicz, Emily M ^a,b   Mortensen, Richard M ^a   Traynor, John R ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

antinociception; G protein; morphine; mu opioid receptor; signaling; transgenic mice

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHAI2 SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHAI3 SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHAO1 SUBUNIT; METHADONE; MORPHINE SULFATE; MU OPIATE RECEPTOR; NALBUPHINE; OPIATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SPINAL CORD; THERMAL STIMULATION; WILD TYPE;

ANALGESICS, OPIOID; ANIMALS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; MALE; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; MICE, TRANSGENIC; PAIN MEASUREMENT; PROTEIN BINDING; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 80051801523     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.91     Document Type: Article

References (38)

1. Adams JU, Paronis CA, Holtzman SG (1990). Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine. J Pharmacol Exp Ther 255: 1027-1032.
2. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
3. Brown DA, Sihra TS (2008). Presynaptic signaling by hetero-trimeric G-proteins. Handb Exp Pharmacol 174: 207-260.
4. Carter BD, Medzihradsky F (1993). Go mediates the coupling of the mu opioid receptor to adenylyl cyclase in cloned neural cells and brain. Proc Natl Acad Sci USA 90: 4062-4066. (Pubitemid 23134166)
5. Chakrabarti S, Prather PL, Yu L, Law PY, Loh HH (1995). Expression of the mu-opioid receptor in CHO cells: ability of mu-opioid ligands to promote alpha-azidoanilido[32P]GTP labeling of multiple G protein alpha subunits. J Neurochem 64: 2534-2543.
6. Clark MJ, Furman CA, Gilson TD, Traynor JR (2006a). Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation. J Pharmacol Exp Ther 317: 858.
7. Clark MJ, Linderman JJ, Traynor JR (2008). Endogenous regulators of G protein signaling differentially modulate full and partial mu-opioid agonists at adenylyl cyclase as predicted by a collision coupling model. Mol Pharmacol 73: 1538-1548. (Pubitemid 351574843)
8. Clark MJ, Traynor JR (2006b). Mediation of adenylyl cyclase sensitization by PTX-insensitive GalphaoA, Galphai1, Galphai2 or Galphai3. J Neurochem 99: 1494-1504.
9. Connor M, Christie MD (1999). Opioid receptor signalling mechanisms. Clin Exp Pharmacol Physiol 26: 493-499. (Pubitemid 29309619)
10. Duan SZ, Christe M, Milstone DS, Mortensen RM (2007). Go but not Gi2 or Gi3 is required for muscarinic regulation of heart rate and heart rate variability in mice. Biochem Biophys Res Commun 357: 139-143. (Pubitemid 46574510)
11. Dykstra LA, Preston KL, Bigelow GE (1997). Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Psychopharmacology (Berl) 130: 14-27. (Pubitemid 27107781)
12. Garzon J, de Antonio I, Sanchez-Blazquez P (2000). In vivo modulation of G proteins and opioid receptor function by antisense oligodeoxynucleotides. Methods Enzymol 314: 3-20.
13. Garzon J, Martinez-Pena Y, Sanchez-Blazquez P (1997). Gx/z is regulated by mu but not delta opioid receptors in the stimulation of the low Km GTPase activity in mouse periaqueductal grey matter. Eur J Neurosci 9: 1194-1200.
14. Gierschik P, Milligan G, Pines M, Goldsmith P, Codina J, Klee W et al (1986). Use of specific antibodies to quantitate the guanine nucleotide-binding protein Go in brain. Proc Natl Acad Sci USA 83: 2258-2262. (Pubitemid 16020874)
15. Hendry IA, Kelleher KL, Bartlett SE, Leck KJ, Reynolds AJ, Heydon K et al (2000). Hypertolerance to morphine in G(z alpha)-deficient mice. Brain Res 870: 10-19.
16. Hescheler J, Rosenthal W, Trautwein W, Schultz G (1987). The GTP-binding protein, Go, regulates neuronal calcium channels. Nature 325: 445-447. (Pubitemid 17056412)
17. Hwang JI, Choi S, Fraser ID, Chang MS, Simon MI (2005). Silencing the expression of multiple Gbeta-subunits eliminates signaling mediated by all four families of G proteins. Proc Natl Acad Sci USA 102: 9493-9498. (Pubitemid 40981709)
18. Jiang M, Bajpayee NS (2009). Molecular mechanisms of Go signaling. Neurosignals 17: 23-41.
19. Jiang M, Gold MS, Boulay G, Spicher K, Peyton M, Brabet P et al (1998). Multiple neurological abnormalities in mice deficient in the G protein Go. Proc Natl Acad Sci USA 95: 3269-3274.
20. Jiang M, Spicher K, Boulay G, Wang Y, Birnbaumer L (2001). Most central nervous system D2 dopamine receptors are coupled to their effectors by Go. Proc Natl Acad Sci USA 98: 3577-3582. (Pubitemid 32220887)
21. Kest B, Smith SB, Schorscher-Petcu A, Austin JS, Ritchie J, Klein G et al (2009). Gnao1 (G alphaO protein) is a likely genetic contributor to variation in physical dependence on opioids in mice. Neuroscience 162: 1255-1264.
22. Laugwitz KL, Offermanns S, Spicher K, Schultz G (1993). mu and delta opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma SH-SY5Y cells. Neuron 10: 233-242. (Pubitemid 23079545)
23. Lester PA, Traynor JR (2006). Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. Brain Res 1073-1074: 290-296.
24. McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C et al (2010). mu-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 78: 756-766.
25. Moises HC, Rusin KI, Macdonald RL (1994). mu-Opioid receptor-mediated reduction of neuronal calcium current occurs via a G(o)-type GTP-binding protein. J Neurosci 14: 3842-3851.
26. Mortensen RM, Conner DA, Chao S, Geisterfer-Lowrance AA, Seidman JG (1992). Production of homozygous mutant ES cells with a single targeting construct. Mol Cell Biol 12: 2391-2395.
27. Peckham EM, Traynor JR (2006). Comparison of the antinocicep-tive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther 316: 1195-1201. (Pubitemid 43345294)
28. Raffa RB, Martinez RP, Connelly CD (1994). G-protein antisense oligodeoxyribonucleotides and mu-opioid supraspinal antinoci-ception. Eur J Pharmacol 258: R5-R7. (Pubitemid 2095555)
29. Sanchez-Blazquez P, Garcia-Espana A, Garzon J (1995). In vivo injection of antisense oligodeoxynucleotides to G alpha subunits and supraspinal analgesia evoked by mu and delta opioid agonists. J Pharmacol Exp Ther 275: 1590-1596. (Pubitemid 26129952)
30. Sanchez-Blazquez P, Gomez-Serranillos P, Garzon J (2001). Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res Bull 54: 229-235. (Pubitemid 32223929)
31. Selley DE, Liu Q, Childers SR (1998). Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther 285: 496-505. (Pubitemid 28237424)
32. Selley DE, Sim LJ, Xiao R, Liu Q, Childers SR (1997). Mu-opioid receptor-stimulated guanosine-50-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduc-tion mechanisms underlying agonist efficacy. Mol Pharmacol 51: 87-96. (Pubitemid 27049549)
33. Sowell MO, Ye C, Ricupero DA, Hansen S, Quinn SJ, Vassilev PM et al (1997). Targeted inactivation of alphai2 or alphai3 disrupts activation of the cardiac muscarinic K+ channel, IK+Ach, in intact cells. Proc Natl Acad Sci USA 94: 7921-7926.
34. Standifer KM, Rossi GC, Pasternak GW (1996). Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein alpha subunits. Mol Pharmacol 50: 293-298. (Pubitemid 26265133)
35. Traynor JR, Nahorski SR (1995). Modulation by mu-opioid agonists of guanosine-50-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 47: 848-854.
36. Valenzuela D, Han X, Mende U, Fankhauser C, Mashimo H, Huang P et al (1997). G alpha(o) is necessary for muscarinic regulation of Ca2+ channels in mouse heart. Proc Natl Acad Sci USA 94: 1727-1732.
37. Yu VC, Sadee W (1988). Efficacy and tolerance of narcotic analgesics at the mu opioid receptor in differentiated human neuroblastoma cells. J Pharmacol Exp Ther 245: 350-355.
38. Zhao B, Wang HB, Lu YJ, Hu JW, Bao L, Zhang X (2011). Transport of receptors, receptor signaling complexes and ion channels via neuropeptide-secretory vesicles. Cell Res 21: 741-753.